Kornimate/medical-research-clean huggingface dataset:
sonographic examination of median nerve variations

Conditions: Carpal Tunnel Syndrome

Summary: the aim of the study is to evaluate the prevalence of bifid median nerve in patients diagnosed with carpal tunnel syndrome (cts) and whether it has a higher prevalence in cts patients than in asymptomatic individuals, and to evaluate the characteristics of the bifid median nerve found and whether median nerve variations are predisposing factors in the development of cts.

patients diagnosed with carpal tunnel syndrome electrophysiologically who applied to etlik city hospital physical therapy outpatient clinic will be included in the study.there are no sensitive groups.the research period was determined as 1 year.the sample size was done using g power 3.1.9.4 statistical power analysis program for windows.based on the study conducted by walker fo et al., the number of patients that would provide a significant difference (with a margin of error of 5% type 1 and 20% type 2, a study power of 80% and a confidence interval of 95%) was found to be 129 patients in total.demographic and clinical characteristics of patients who meet the inclusion criteria and fill out the "informed consent forum" will be recorded.general pain of the patients will be evaluated with the visual analogue scale (global pain), symptom severity and functional status will be evaluated with the boston carpal tunnel questionnaire, and hand grip strength measurement will be evaluated with a dynamometer.the patient hand diagram will be marked according to the patient's sensory symptoms.median nerve cross-sectional area will be measured at the pisiform level with ultrasound, and distal motor latency and sensory nerve conduction velocity will be measured with emg and recorded.median nerve stiffness will be evaluated by real-time elastography.

Eligibility criteria:
inclusion criteria: * having typical carpal tunnel sydnrome symptoms lasting longer than 3 months * carpal tunnel syndrome diagnosed with emg * being a male/female \>18 years of age exclusion criteria: * history of polyneuropathy, brachial plexopathy, thoracic outlet syndrome, or surgery in the wrist area * presence of inflammatory arthritis, hypothyroidism, pregnancy, rheumatological disorders, diabetes mellitus * presence of peripheral vascular disease

Keywords: bifid median nerve carpal tunnel syndrome variations of median nerve sonography
hyperglycemic response and steroid administration after surgery (dexglysurgery)

Conditions: Diabetes; Healthy

Summary: the hyperglycemic response to surgery and the added effect of low-dose steroids (dexamethasone 4 to 8mg), and whether these differ in diabetics and nondiabetics remain unclear. therefore, we prospectively evaluate the intraoperative and postoperative serum glucose concentrations in diabetics and nondiabetics that received intravenous steroid administration. this multicentre study include \> 250 patients.primary endpoiunt was glucose concentration at h6 after surgery. secondary endpoints were glucose concentration at h12 and at h24 and effect of anesthesia (regional anesthesia)


Eligibility criteria:
inclusion criteria: * elective surgery under anesthesia exclusion criteria: * \< 50 kg * emergency * insulin therapy * cardiac surgery * refusal * hyperglycemia\> 2g/l

Keywords: diabetes anesthesia surgery glucose
preparing family caregivers to make medical decisions for their loved ones

Conditions: Neoplasms; Heart Failure; Kidney Diseases; Lung Diseases

Summary: the overarching goal of the project is to improve the process and experience of surrogate decision-making by family caregivers. since feeling unprepared to make surrogate decisions is a major contributor to caregiver stress, the primary outcome is caregiver self-efficacy --i.e., caregivers' assessment of how well prepared they feel to serve effectively as a surrogate decision-maker. through follow-on renewal funding, we are now also qualitatively examining family caregivers' experience with surrogate decision-making.

the long-term goal is to help family caregivers of seriously ill patients be better prepared to serve as surrogate decision-makers when their loved ones can no longer make medical decisions for themselves. research shows that family caregivers find surrogate decision-making highly stressful and emotionally burdensome, in part because they feel unprepared for surrogate decision-making. to date, no studies have determined which advance care planning (acp) process best prepares caregivers for this role. the investigators' prior work shows that a computer-based decision aid can help patients make more informed decisions and communicate their wishes more effectively. the investigators now propose to determine if family caregivers of patients with life-threatening illnesses are better prepared for surrogate decision-making: 1) when they engage in a structured acp process together with patients; and 2) when they use this online decision aid for acp. this will be accomplished via a randomized, controlled trial with a 2 x 2 factorial design comprising 4 groups: standard acp/patient alone (group 1), decision aid/patient alone (group 2), standard acp/patients and caregivers together (group 3), and decision aid/patients and caregivers together (group 4).

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. diagnosis of kidney disease (e.g. chronic kidney disease, end stage renal disease ) or advanced cancer (stage iv disease or having an estimated survival of \<2 years) or severe heart failure (e.g. new york heart assoc. class iii or class iv) or severe lung disease (e.g. stage iii or stage iv copd by modified gold spirometric classification, idiopathic pulmonary fibrosis). 3. able to read and understand english at an 8th grade level (word 26 on either blue or tan version of the wrat-3 reading subtest) 4. neuro-cognitively able to engage in acp (mini mental state exam (mmse) score \>23) 5. no active suicidal ideations (i.e., score of 0 or 1 on item 9 of the bdi-ii). exclusion criteria: * failure on any of the above inclusion criteria.

Keywords: advance care planning living will family caregiver advance directive surrogate decision maker proxy self-efficacy
ultrasound-guided dry needling vs prp for refractory lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: this single-center, randomized, prospective study was conducted between january 2022 and september 2023 with ethics committee approval. adults aged 18-65 with a clinical diagnosis of lateral epicondylitis-characterized by lateral elbow pain exacerbated by resisted wrist or middle finger extension-and who had not responded to at least six weeks of conservative treatment were included. exclusion criteria included cervical disc disease, nerve entrapment, arthrosis, uncontrolled metabolic disorders, bleeding disorders, prior elbow surgery or injection, pregnancy, cognitive impairment, or compromised skin at the injection site. a g\*power sample size calculation determined that at least 50 patients were needed. participants were randomly assigned to two groups: 25 received ultrasound-guided dry needling and 25 received platelet-rich plasma (prp) injections. all participants gave informed consent, and the study adhered to the declaration of helsinki. baseline demographic and clinical data were collected, and the diagnosis was confirmed using mills, maudsley, and thomsen tests, along with grip-strength assessment. pain and function were evaluated using the prtee, visual analog scale (vas), and quickdash questionnaires at baseline, and at 1, 3, and 6 months post-treatment. ultrasound imaging was used to identify tendinopathic changes. local anesthesia was administered with 2 ml of prilocaine. in the dry needling group, an 18-gauge needle was used to fenestrate the tendon with 40-50 passes in a "peppering" motion under continuous ultrasound guidance. in the prp group, 15 ml of blood was drawn, centrifuged, and approximately 2 ml of prp was injected into the lesion under ultrasound guidance. after the procedure, patients were advised to apply ice, perform passive stretching, avoid lifting heavy objects, and refrain from nsaid use for two weeks. gradual return to normal activities was encouraged thereafter to restore full elbow function.


Eligibility criteria:
inclusion criteria: 18 and 65 years of age, having a clinical diagnosis of lateral epicondylitis based on localized lateral elbow pain exacerbated by resisted wrist or middle finger extension and tenderness over the lateral epicondyle on physical examination, and failure to respond to at least six weeks of conservative treatment. - exclusion criteria:the presence of cervical discopathy or upper extremity nerve entrapment, radiocapitellar arthrosis, uncontrolled metabolic diseases (hypothyroidism, diabetes), bleeding diathesis, a history of previous elbow injection or surgery, pregnancy or lactation, cognitive impairment, and skin compromise at the injection site -
modified rekovelle and menopur combination protocol to avoid monitoring before day 10 of stimulation

Conditions: Infertility; IVF

Summary: follitropin delta (rekovelle) algorithm established by ferring provides personalized gonadotrophin doses based on each patient's weight and amh. as a result, risks of stimulation failure or ovarian hyperstimulation syndrome (ohss) during an in vitro fertilization (ivf) cycle are minimized. as a standard practice for ohss prevention at clinique ovo, women undergoing ivf will have a scheduled ultrasound and blood test on the sixth day of their stimulation treatment. however, with the determination of the rekovelle and menopur algorithm, the risks of ohss before the tenth day have been considerably minimized.

the purpose of this study is to evaluate the necessity of programming an ultrasound and blood test prior to the tenth day of ovarian stimulation when women are on personalized doses of rekovelle and menopur duting an antagonist ivf cycle. based on the results of the analysis, we will assess the economic impact that programming an ultrasound and blood test at day 10 might have.

Eligibility criteria:
inclusion criteria: * women of 18 years of age or older having provided consent to chart access for scientific publication in the ivf consent form * antagonist ivf cycle using combination of rekovelle and menopur for stimulation according to the modified protocol employed at clinique ovo without deviation * presence of both ovaries exclusion criteria: * second cycle of duo-stim ivf
safety study of eteplirsen to treat early stage duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy (DMD)

Summary: this is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage duchenne muscular dystrophy (dmd) who are amenable to exon 51 skipping.

safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients. clinical efficacy, including functional tests and mri, will be assessed at regularly scheduled study visits. patients will undergo one baseline and one follow-up muscle biopsy. population and serial pk will be collected.

Eligibility criteria:
inclusion criteria: * male 4-6 years of age. * diagnosis of dmd, genotypically confirmed. * stable dose of oral corticosteroids for at least 12 weeks or has not received corticosteroids for at least 12 weeks. * intact right and left biceps muscles or two alternative upper arm muscle groups. * parent that is willing to provide consent and comply with study procedures. exclusion criteria: * use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids). * previous or current treatment with any other experimental treatments within 12 weeks or participation in any other clinical trial within 6 months. * major surgery within 3 months prior to the first dose of study drug, or planned surgery during this study which would interfere with the ability to perform study activities. * presence of other clinically significant illness.

Keywords: dmd duchenne muscular dystrophy eteplirsen dystrophin exon 51
the impact of platelet functions on spontaneous ductal closure in preterm infants

Conditions: Patent Ductus Arterioses

Summary: although thrombocytopenia has been reported as a risk factor for patent ductus arterioses, there is lack of data on the function of platelets in ductal closure. information on functions of platelets in ductal closure may change the known model for ductus arterioses and may affect the treatment modalities.

patent ductus arterioses is a common problem which involves both pulmonary and cardiac outcomes in preterm infants. although thrombocytopenia has been reported as a risk factor for patent ductus arterioses, there is lack of data on the function of platelets in ductal closure. the investigators aim to investigate the relation between thrombocytopenia and platelet functions in pathogenesis of spontaneous ductal closure. the investigators hypothesize that information on functions of platelets in ductal closure may change the known model for ductus arterioses and may affect the treatment modalities.

Eligibility criteria:
inclusion criteria: * gestational age lower than 30 weeks and birth weight lower than 1500 g * obtained informed consent exclusion criteria: * any received medical treatment in first 2 days of life * death in first 2 days * patients who received any thrombocyte or fresh frozen plasma suspensions * any known genetic thrombocyte disorder in the family

Keywords: patent ductus arterioses ductal closure thrombocyte
a prospective multicenter trial evaluating helios biodegradable polymer ses safety and effectiveness in cad treatment

Conditions: Coronary Artery Disease

Summary: research topic:helios after registration of clinical research bidders:kinhely bio-tech co.ltd study design:a prospective single treatment group multicenter clinical study number of patients:included in the subjects of 800 cases main research purpose:evaluation of safety and effectiveness mainly studies the finish:1 year target lesion of the failure inclusion criteria : one:gender not limited at the age of 18 to 80 two:myocardial ischemia or angina symptoms of coronary artery disease three:a narrow is less than 50% treated with stents four:comply with the instructions five:voluntarily signed the informed consent form exclusion criteria: one:pregnant women two:cardiac shock three:against a suppository medicines or allergies four:participated in other test research in the first 6 months five:within 6 months after pci plans to accept non cardiac surgery six:non-compliant patient follow-up time:a month for 6 months and 9 months to 1 year to 2 years follow-up progress plan:all center within 6 months after start of complete into the group

no desired

Eligibility criteria:
inclusion criteria: * any age 18 to 80 sex myocardial ischemia or angina pectoris of coronary artery disease an application stents diameter stenosis greater than 50% comply with the instructions voluntarily signed the informed consent form exclusion criteria: * pregnant women cardiac shock intolerance to antithrombotic therapy or allergies 6 months prior to the start of the study involved in other studies within 6 months after pci plans to accept non cardiac surgery non-compliant patient

Keywords: coronary artery disease pci stent
neurolinguistic programming on labor pain

Conditions: Neurolinguistic Programming; Labor Pain

Summary: the effect of neuro linguistic programming on labour pain, fear, duration and maternal satisfaction

in this study, it is aimed to determine the effect of neuro linguistic programming on labour pain, fear, duration and maternal satisfaction. sample size: * the sample size of the study is 124 (for primiparous=62, multiparous=62). * frist, primiparous women who applied to the hospital for vaginal delivery will be divided into 2 arms as 31 experimental group and 31 control group. * second, multiparous women who applied to the hospital for vaginal delivery will be divided into 2 arms as 31 experimental group and 31 control group. data collection tools; * introductory information form, * visual analog scale for pain, * wijma birth expectation/experience scale b version, * birth satisfaction scale application time: * the neurolinguistic programming will be applied to the experimental group. nlp application will be done when the cervical opening is 4 cm, when the cervical opening is 5-6 cm, when the cervical opening is 7-8 cm.nlp application will be done three times in total. each session will last 20 minutes * no neurolinguistic programming will be applied to the control group. measurement time: * introductory information form will be completed by the woman when the cervical dilatation is 3-4 cm. * vas for pain will be measured before and immediately after the application when cervical dilatation is 4 cm; before and immediately after the application when cervical dilatation is 5-6 cm; before and immediately after the application when cervical dilatation is 7-8 cm; when cervical dilatation is 9-10 cm. * wijma birth expectation/experience scale b version and birth satisfaction scale will be completed by the woman in the postnatal ward at approximately the second hour postpartum after the birth has taken place. * the labour duration will be started for the mother who comes to the delivery room when the cervical opening is 4 cm and the total labour duration will be measured in minutes after the birth occurs. * the control group will not be administered nlp only, but the measurements will be completed as in the experimental group.

Eligibility criteria:
inclusion criteria: * pregnant women who give birth vaginally, * whose birth takes place in the delivery room unit, * who are 19 years of age or older and 35 years of age or younger, * who are born at 37 and above gestational weeks, * who give singleton birth, * who do not have chronic diseases and any complications in this pregnancy and postpartum period exclusion criteria: * mothers who wish to leave the study voluntarily at any stage after being included in the study, * who develop any health problems in themselves or their babies during the birth and postnatal period will be excluded from the scope.

Keywords: neuro linguistic programming labour pain labour fear labour satisfaction labour duration
asciminib prospective non interventional study as 3rd line therapy or more to treat adult patients with cml- cp in real world setting in france

Conditions: Chronic Myeloid Leukemia

Summary: the purpose of this study is to enhance the knowledge on asciminib treatment in a broader and real-life population by collecting additional data to characterize the treatment patterns of patients treated with asciminib, with a primary objective represented by maintenance on treatment at 12 months.

the assure-3 study is a national, multicentric, non-interventional, prospective study in real-life conditions with primary data collection in adult patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (ph+ cml-cp) previously treated with two or more tyrosine kinase inhibitors (tkis). it will be conducted in france with hematologists, onco-hematologists, physicians with documented involvement in managing ph+ cml-cp patients in routine practice, practicing in public or private health care institutions. each patient will be followed during 15 months at m0, m1 and then every 3 months (rhythm of visits according to the routine clinical care), or until premature discontinuation of asciminib treatment. historical data will be abstracted retrospectively by the participating physicians from patient files, to collect information using an electronic case report form (ecrf). primary data will be collected during inclusion and follow-up visits

Eligibility criteria:
inclusion criteria: 1. patient aged ≥ 18 years at inclusion, 2. patient with ph+ cml-cp previously treated with two or more tkis, 3. patient for whom a decision has been taken by the treating physician (investigator) to initiate treatment with asciminib according to his own practice, the drug label / summary of product characteristics (smpc), and regardless of study participation, 4. patient having given their non objection to participate to the study exclusion criteria: 1. patient with cml in accelerated phase (ap) or blastic phase (bp) at enrolment, 2. patient with known history of t315i mutation, 3. patient who previously received asciminib treatment, 4. patient currently participating to an interventional clinical trial, 5. patient with known contra-indication to asciminib according to the smpc.

Keywords: chronic myeloid leukemia cml asciminib france
mucosal inflammation in children with osa

Conditions: Obstructive Sleep Apnea

Summary: objectives: variability of clinical phenotypes in childhood obstructive sleep apnoea (osa) has prompted research for biomarkers to identify patients at risk of developing osa-related complications. upper airway inflammation is documented in children with osa. whether it is related to end-organ morbidities and systemic inflammation is under-explored. the primary objectives of our study are 1)to evaluate inflammatory biomarkers with the use of nasal epithelial lining fluid (nelf) collected by nasal strips as a representation of upper airway inflammation in children with osa compared to non-osa controls; 2) to evaluate the associations between nelf biomarkers with ambulatory blood pressure (abp) outcomes in children with osa. hypothesis to be tested: inflammatory biomarkers in nelf in children with osa are altered when compared with non-osa controls and correlated with abp outcomes. design and subjects: a prospective case-control study. non-obese chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (psg) confirmed osa (oahi of ≥1/hour) will be recruited as cases. non-osa children with oahi \< 1 event/h will be recruited as controls. all subjects will undergo evaluation including questionnaires, anthropometric measurements, psg, 24-hour abp measurement, blood and nelf sampling. primary outcome measure: profile of inflammatory biomarkers in the nelf. analysis: correlations between nelf inflammatory biomarkers with polysomnographic and abp measurements will be evaluated by regression analysis. expected results: this study will provide novel and important information regarding upper airway inflammatory biomarkers in children with osa and their relationship with blood pressure outcomes.


Eligibility criteria:
inclusion criteria: * children aged 6-11 years old exclusion criteria: * previous upper airway surgery, genetic or syndromal disease, congenital or acquired neuromuscular disease, suspected or confirmed congenital or acquired immunodeficiency, obesity (bmi z-score ≥1.645), known metabolic syndrome, craniofacial abnormalities, structural or congenital heart disease, use of medications or therapy that could affect immunity such as systemic corticosteroids, chemotherapy, radiation therapy, intravenous immunoglobulins.
recurrence of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: analysis of the risk factors of intra-hepatic distant recurrence (idr) of hepatocellular carcinoma within 1 year after radiofrequency ablation.


Eligibility criteria:
inclusion criteria: 1. proved diagnosis of hcc according to aasld practice guidelines (bruix and sherman, 2005). 2. patients underwent rfa for hcc with bclc (the barcelona-clinic- liver-cancer staging system) stage a (bruix and sherman, 2005) with no eligibility or ability to do transplantation or resection. 3. patients should be followed-up for more than 12 months to exclude early recurrence i.e. recurrence within 1 year. 4. patients with inr \ 50%. 5. platelet count \> 50000 cell/mm3. exclusion criteria: 1. presence of extra-hepatic metastasis or gross vascular invasion. 2. child class c patients. 3. follow up period of less than 12 months.

Keywords: hepatocellular cacinoma radiofrequancy ablation intrahepatic recurrence